Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Bartlett JMS, Xu K, Wong J, Pond G, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburg A, Markopoulos C, Dirix L, van de Velde CJH, Rea D, Schnabel CA, Treuner K, Bayani J. Bartlett JMS, et al. Among authors: salunga r. Clin Cancer Res. 2024 Apr 15;30(8):1509-1517. doi: 10.1158/1078-0432.CCR-23-2436. Clin Cancer Res. 2024. PMID: 38345755 Free PMC article.
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Bartlett JMS, et al. Among authors: salunga rc. Clin Cancer Res. 2022 May 2;28(9):1871-1880. doi: 10.1158/1078-0432.CCR-21-3385. Clin Cancer Res. 2022. PMID: 35144966 Free PMC article. Clinical Trial.
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, Salunga R, Brachtel EF, Pirrie SJ, Schnabel CA, Rea DW. Bartlett JMS, et al. Among authors: salunga r. Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289. Ann Oncol. 2019. PMID: 31504126 Free PMC article. Clinical Trial.
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Sgroi DC, et al. Among authors: salunga r. Breast Cancer Res. 2022 Dec 16;24(1):90. doi: 10.1186/s13058-022-01589-x. Breast Cancer Res. 2022. PMID: 36527133 Free PMC article.
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC. Ma XJ, et al. Among authors: salunga r. Cancer Cell. 2004 Jun;5(6):607-16. doi: 10.1016/j.ccr.2004.05.015. Cancer Cell. 2004. PMID: 15193263 Free article.
15 results